Clinical Trials Sponsored by Mylan Bertek Pharmaceuticals

Total 435 results

Mylan Bertek Pharmaceuticals

Completed

Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months

Parkinson Disease

United Kingdom
Mylan Bertek Pharmaceuticals

Completed

A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

Parkinson Disease
Mylan Bertek Pharmaceuticals

Completed

A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.

Parkinson Disease
Mylan Bertek Pharmaceuticals

Completed

Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease

Parkinson Disease

United States
Mylan Inc.
Mylan Bertek Pharmaceuticals

Terminated

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

Burns

United States
Mylan Pharmaceuticals Inc
Mylan GmbH

Completed

Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion

Healthy
Mylan Pharmaceuticals Inc

Completed

A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers

Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis
Mylan Pharmaceuticals Inc

Completed

Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg

Healthy

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

HIV Infections | Hepatitis C

France, Spain, United States, Germany
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)

Healthy

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Hepatitis C

Australia, Canada, France, Italy, Poland, United Kingdom, Germany, United States, Spain, Israel, Argentina, Puerto Rico, Austria
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Virology Follow up Study in Subjects Previously Treated With Telaprevir

Hepatitis C

United States, France, Canada, Germany, Puerto Rico
Mylan Pharmaceuticals Inc

Completed

Food Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study Metformin Hydrochloride ER Tablets 750 mg and Glucophage XR 750 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

Healthy

United States

3

Subscribe